Innovent Biologics Inc. and Pfizer Inc. have entered into a strategic global licensing and collaboration agreement for the research and development of 12 new breakthrough early-stage and de novo cancer medicines.
Innovent, Pfizer partner on 12 early-stage cancer programs
